Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients. Our two most advanced programs include a diabetes treatment candidate and a cosmetic skin lightening agent.
Our sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and in Europe (November 2013). In 2014, Sirona licensed the SGLT2 Inhibitor to Wabang Biopharmaceuticals for development and commercialization of this anti-diabetic inhibitor exclusively in the People’s Republic of China (PRC). In exchange for this license, Wanbang Biopharma has provided an upfront and will give milestone payments of up to US$9.5M in addition to royalty payments for product sales.
In terms of the skin lightening market, Sirona Biochem has made significant advancements in this area. Recognized for the scientific innovation at our laboratory in France, the French government awarded our team an innovation grant worth CDN$1.9 Million to develop our cosmetic skin lightener program to a commercial ready stage. Since then, numerous efficacy and stability studies have been completed with results showing superiority over popular commercial products. In 2014, Sirona and Obagi Medical Products (Obagi) executed a global exclusive licensing agreement for the commercialization of skin lightening compound TFC-849. Sirona Biochem has received a licensing fee and will receive ongoing royalty payments for global product sales from Obagi Medical Products.
Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high.
Sirona has also teamed up with Bloom Burton (www.bloomburton.com), Canada’s leading healthcare-specialized investment banking group, to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.